# Ocular Therapeutix Inc. (OCUL)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $8.76 (+0.17%)

> Ocular Therapeutix Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye. It specializes in ophthalmology, particularly advancing treatments for retinal disorders such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR). The company's pipeline features AXPAXLI (OTX-TKI), a tyrosine kinase inhibitor delivered via intravitreal bioresorbable implant designed for extended durability, currently in late-stage Phase 3 clinical programs including the SOL-1 superiority trial and HELIOS registrational program. Ocular Therapeutix Inc. also markets DEXTENZA, a commercial intracanalicular insert for ocular pain and inflammation post-surgery. Additional candidates like OTX-TP target glaucoma and dry eye disease. Headquartered in Bedford, Massachusetts and founded in 2006, the company plays a key role in the retinal therapeutics market by leveraging bioresorbable hydrogel technology to improve patient outcomes and reduce treatment burden through sustained drug delivery systems.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/OCUL)